Cigna-Express Scripts deal has already cost $201M

Amy Baxter | | Health Exec | Policy & Regulations
Money

The $67 billion mega-merger between Cigna and Express Scripts has already cost a staggering $201 million, Axios reported.

The deal, which has already been approved by shareholders and cleared by nearly half of the necessary regulators, is anticipated to close in the second half of 2018. Cigna cited the estimated actual transaction costs incurred by the deal in 2018 at $201 million in a filing with the Securities and Exchange Commission (SEC).

The transaction costs will likely be passed onto consumers, Axios reported. The deal brings together a major insurance provider and a large pharmacy benefits manager (PBM) at a time when the healthcare industry is seeing rapid consolidation. Another large PBM, CVS Health, is attempting to acquire insurance provider Aetna for $69 billion.

See the full report below:

The merger tab for Cigna and Express Scripts

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Report: UnitedHealth under investigation by DOJ for Medicare Advantage upcoding
FDA approves first therapy for very rare lipid storage disorder
FDA announces Class I recall of Boston Scientific pacemakers—replacement may be necessary
FDA ends semaglutide shortage, closing the door on compounded Wegovy, Ozempic
American Heart Association highlights importance of NIH as battle over Trump funding cuts continues
Federal judge sides with FTC; case against PBMs to move forward

Around the web

Cardiovascular Business
American Heart Association highlights importance of NIH as battle over Trump funding cuts continues

“Now more than ever, we must recognize that our country’s leadership in groundbreaking medical research spurs scientific innovation, improves public health and creates new innovations that save and improve lives nationwide,” Joseph C. Wu, MD, PhD, explained in a statement. 

Cardiovascular Business
Cardiologist questions FDA’s approval process for high-risk medical devices

The technology used to diagnose, treat and manage cardiovascular disease is always evolving, keeping FDA officials quite busy. But have the agency's standards been slipping in recent years? A cardiologist with Cedars-Sinai Medical Center explored that very question.

Cardiovascular Business
FDA announces new recall of Johnson & Johnson heart pumps over safety concerns

No devices need to be returned at this time. However, the FDA warned, using these heart pumps without reviewing the updated instructions could result in "serious injury or death.”